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The human papillomavirus is a necessary cause of cervical cancer leading to >12,000 cervical 
cancer diagnoses and >4,000 deaths in the United States in 2007. In 2006, the first HPV vaccine 
was approved by the US FDA, which prevents the acquisition of high-risk types of HPV (16/18) 
that cause 70% cervical cancer cases in the US and 50% of precancerous lesions. Our objectives 
were to examine HPV type distribution among women with cervical intraepithelial neoplasia 2/3 
(CIN2+) by area-based measures of race, ethnicity, and poverty and individual level 
characteristics.   
 
Methods 
In 2008, the Connecticut Department of Public Health (DPH) mandated reporting of CIN2+. 
Diagnostic specimens from women aged 18–39 years residing in New Haven County and 
reported during 2008–2010 were sent to the CDC to ascertain HPV type(s) which were 
subsequently coded as vaccine type (16/18 with or without other HPV types) or non-vaccine type 
(all others). Cases were also geocoded to census tracts (neighborhood level) and linked to 
measures of percent of the population living below the federal poverty level, proportion of 
population Hispanic, and proportion of population black. Statistical analyses included chi-square 
tests, logistic regression, and generalized estimating equations. 
 
Results 
Our sample consisted of 917 women who had HPV typing data available. Among these women, 
41.9% had an HPV type (16 or 18) that is covered by the vaccine. In areas where 20% or greater 
of the population is living below poverty level, a significantly higher proportion of women had 
non-vaccine type HPV (60%) compared to women living in areas where less than 5% of women 
lived below poverty (50.5%%, p=0.05). Individual race/ethnicity analysis shows that black and 
Hispanic women were more likely to have non-vaccine type HPV (63.8% and 61.2% 
respectively). Analysis by area-based race and ethnicity showed that women who live in areas 
with higher proportions of black or Hispanic populations had higher proportions of non-vaccine 
type HPV. Specific non-vaccine HPV types were more prevalent in non-Hispanic blacks and 
Hispanics compared to non-Hispanic whites. Some main types included 35, 52, and 58 that 
together accounted for 35.8% of the HPV found among black women, 23.3% of HPV among 
Hispanic women and only 14.8% of HPV among white women. 
 
Conclusions 
Area-based results showed that women who live in areas with higher proportions of the 
population black, Hispanic or living below poverty have higher percentages of non-vaccine type 
HPV than vaccine type HPV (16/18). Similarly for individual level characteristics, non-Hispanic 
black and Hispanic women were also more likely to have non-vaccine type HPV compared to 
white women. HPV types not included in the current vaccines are causing a significant amount 
of precancerous lesion morbidity among minority women. These baseline differences need to be 
taken into account when evaluating the impact of the current HPV vaccines and when 
considering the development of future multi-valent HPV vaccines.  
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Introduction 
HPV Epidemiology and Background 
Genital human papillomavirus (HPV) is the most common sexually transmitted infection 
(STI) in the United States and is the necessary cause of cervical cancer and precancerous cervical 
lesions. In the United States, it is estimated that 20 million people have genital HPV currently 
with 6 million new infections occurring every year [1]. There are more than 100 types of HPV 
with 40 types that are sexually transmissible. Genital HPV prevalence rates range from 27 to 
almost 45 percent with the highest prevalence rates found in females aged 20 to 24 years [2]. It is 
also estimated that nearly 80% of all people who have ever been sexually active have had one or 
more HPV types in their lifetime [1].  
 In the U.S. in 2004, there were an estimated 12,000 incident cases of cervical cancer and 
3,850 attributable deaths [3] even though mortality due to cervical cancer is largely preventable 
in the U.S. due to the availability of routine screening and proper treatment [4]. High-risk and 
low-risk HPV types are categorized depending on their association with different disease 
outcomes including cervical cancer. Persistent infection with high-risk HPV types 16 and 18 
cause approximately 70% of cervical cancer cases [5] and 50% of cervical precancerous lesions 
worldwide [6]. However, there are 12 other HPV types that the International Agency for 
Research on Cancer (IARC) deems carcinogenic [7, 8]. These types include HPV-31, -33, -35, -
39, -45, -51, -52, -56, -58, -59, -66, and -68, however, their respective prevalence in 
precancerous lesions has not been completely determined [9]. Low risk HPV includes non-
oncogenic types, such as 6 and 11 that are responsible for genital warts [5].  
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HPV Vaccines 
 In June 2006, the U.S. Food and Drug Administration (FDA) approved the first 
prophylactic HPV vaccine that protects against HPV types 6, 11, 16, and 18 [10]. Three years 
later the FDA approved the second vaccine, which protects against the two most common 
carcinogenic types, 16 and 18 [11]. Both vaccines have very high levels of efficacy and have the 
potential to reduce cervical cancer and precancerous lesion incidence as shown by early evidence 
from Australia’s intensive HPV vaccination program [12]. Australia was the first country to 
implement a universal free HPV vaccination program for all females aged 12-26 using the 
quadrivalent vaccine and a recent study done shows the program’s early successes. The study 
results show a small yet significant decrease in incidence of high-grade cervical abnormalities in 
girls younger than 18 years within the first 3 years of the program suggesting the impact that the 
vaccine can have when given as recommended to young girls before they become sexually active 
[12]. Currently, a new 9-valent HPV vaccine developed by Merck is in phase III of trials 
although no definitive results have been released. According to Merck’s website, they plan to 
apply for a Biologic License Application (BLA) in 2012 suggesting that the phase III trials have 
produced favorable results[13]. 
 
Cervical Cancer Disparities in The United States 
Women who live in poverty and who are racial and/or ethnic minorities have higher rates 
of cervical cancer morbidity and mortality [14]. Over the years these rates have decreased due to 
increased screening coverage [3], however non-Hispanic black and Hispanic women still have a 
higher morbidity and mortality burden than do non-Hispanic white women. Data collected in the 
United Sates from 1992-2003 show that Hispanic women had the highest incidence of cervical 
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cancer overall (24.2/100,000) as well as the highest incidence of the two most common 
histologic types of cervical cancer, squamous cell carcinoma (18.3/100,000) and adenocarcinoma 
(4.6/100,000) [15]. Non-Hispanic black women have the second highest overall cervical cancer 
incidence (16.3/100,000) and squamous cell carcinoma incidence (12.6/100,000), while non-
Hispanic white women had the lowest overall cervical cancer (10.8/100,000) and squamous cell 
carcinoma incidence (7.2/100,000) [15]. Furthermore, it has been shown that women who live in 
lower socioeconomic areas have higher rates of late stage cancer diagnoses and lower survival 
rates compared to women in high socioeconomic areas [14]. However, data from 1975-2000 do 
show that the gap between low and high SES women for incidence of cervical cancer and related 
mortalities may be decreasing [14]. Nevertheless, there is a clear racial, ethnic, and 
socioeconomic disparity that exists in cervical cancer incidence and mortality [15]. Furthermore, 
research shows that vaccination completion rates among minority women are lower than non-
minorities, possibly leaving these women more susceptible to the HPV types responsible for the 
majority of cervical cancer cases[16].  
Very few studies done in the United States have described HPV type distribution in 
precancerous CIN2+ lesions among women of different racial and ethnic backgrounds. Guan et 
al. give the most comprehensive look at HPV types found in CIN2+ lesions worldwide, although 
they presented differences on a continent-wide macro scale rather than an individual 
race/ethnicity micro scale [6]. Furthermore, little information exists linking census tract area-
based measures of race, ethnicity, and socioeconomic status to the type distribution of HPV. The 
use of census tract-level measures to assess and monitor socioeconomic (SES) inequalities has 
shown to be a rigorous and accurate way of measuring health disparities in the United States 
[17]. The objective of this analysis is to examine HPV type distribution among women in New 
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Haven County (NHC) who have a reported diagnosis of cervical intraepithelial neoplasia 2/3 
(CIN 2+) by area-based measures of race, ethnicity, and poverty as well as by individual level 
sociodemographic characteristics including age and health insurance. 
 
Methods 
Surveillance for CIN2+/AIS in New Haven County, CT 
The HPV-IMPACT monitoring system was established in 2008 and is a collaboration 
between the Centers for Disease Control (CDC) and five sites of the Emerging Infections 
Program (EIP) with the purpose of monitoring the impact of the HPV vaccines on CIN2+ 
lesions. Connecticut is one of 5 EIP sites and collects data through statewide passive surveillance 
for CIN2+ diagnosis from the 34 pathology labs that exist in Connecticut. In CT on January 1, 
2008 CIN2+ and adenocarcinoma in situ (AIS) were added to the list of mandatory reportable 
conditions. Reports include diagnostic information as well as patient demographic information. 
In addition to statewide surveillance, enhanced surveillance in the New Haven County (NHC) 
catchment area for women aged 18-39 years is conducted and includes medical chart reviews and 
phone interviews to gain additional information including demographic information that is often 
missing on pathology reports. Interview demographic data is considered the most accurate source 
of demographic information but not all women can be reached by telephone, therefore, medical 
records are a useful supplemental source.   
 This analysis from the ongoing project is restricted to women in the catchment area of 
NHC who are aged 18-39 with a reported case of CIN2+/AIS from January 1, 2008 to December 
31, 2010. Because some women have more than one report during this time, the first diagnostic 
report of the highest grade lesion was selected for this analysis.  
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Specimen Selection and Processing 
Histopathology specimens of CIN2+ cases in New Haven County were requested from 
each laboratory. Of 2,223 reported cases, 1,807 (81.3%) cases were eligible for specimens to be 
requested. Of the specimens eligible for request, 1,572 (87%) were requested from pathology 
laboratories and the remaining 234 (13%) were not requested primarily due to a 12-month 
waiting period at a large pathology laboratory and small laboratories where specimens are not 
requested as often. Of the 1,572 requested, the CT HPV-IMPACT site received 1,076 (68.4%) 
specimens; the remainder are still pending (20.8%) or were deemed to have an insufficient 
amount of specimen to provide (10.8%). All of the specimens that were received were sent to the 
CDC for HPV typing. Of the 1,076 sent to the CDC, 919 (85.4%) were typed and 157 (14.6%) 
are pending. Two of the 919 typed specimens were removed from the dataset because of 
duplication or because the case did not live in NHC.  
Blocks representative of the highest grade lesion were chosen for type-specific HPV 
DNA testing. Specimens were prepared at either the diagnostic laboratory of record or at Yale’s 
pathology laboratory and included preparing serial sections of the tissue block. First and last 
sections were stained with hematoxylin and eosin (H&E) and two intervening 10-micron 
unstained sections were placed in sterile microfuge tubes for extraction[18]. After properly 
labeling all slides and tubes, specimens were sent to the CDC for typing and typing tests were 
performed on specimens for which the diagnosis could be confirmed and contained sufficient 
material for typing.  
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HPV Typing Procedures  
HPV typing procedures have been previously described [18]. Briefly, DNA from  
sectioned blocks was extracted and tested immediately or stored at -20°C.  Extracts were used in 
L1 consensus PCR (Roche Linear Array Assay, 450 bp amplicon). The LA assay uses HPV L1 
consensus PCR with biotinylated PGMY09/11 primer sets and β-globin as an internal control for 
sample amplification. All samples were hybridized to the typing strip that included probes for 37 
HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61, 
62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39). Samples positive for the XR 
probe on the LA HPV strip that were also positive for HPV33, 35 and 58 required further 
evaluation to confirm or exclude the presence of HPV52. An HPV52 quantitative PCR was used 
to determine the status of HPV52 in these cases. Samples negative for HPV were retested with 
another L1 consensus PCR system. The LiPA assay uses SPF10 primers and detects 28 HPV 
types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 
71, 73, 74, 81, 82). Samples negative for both the genomic control probe and HPV were 
considered inadequate for evaluation.   
 
Geocoding and area-based poverty, race, ethnicity measures 
Using patient residential addresses obtained from pathology reports, cases were geocoded 
to the census tract level, which is the recommended area unit of measurement when examining 
health disparities using area-based SES measures [17, 19]. Census tracts are small, relatively 
permanent subdivisions of counties that are specifically designed to be homogenous with respect 
to population characteristics, economic status, and living conditions and usually have between 
2,500 and 8,000 residents [20]. The US Census 2006-2010 ACS 5-year estimates were used to 
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determine census tract sociodemographic statistics and included poverty, race and ethnicity 
measurements. Poverty was measured by percentage of population living below the federal 
poverty level, which is determined by household income, family size, and composition. Race 
was measured as percentage of the population that was black and ethnicity was measured as 
percentage of the population that was Hispanic. For each of these area-based measurements, the 
following cut points were used: <5.0%, 5.0-9.9%, 10.0-19.9%, and ≥ 20%. These cut points have 
been utilized by previous area-based CT HPV-IMPACT studies and are the cut-points  
recommended by the Public Health Disparities Geocoding Project for census tract poverty-level 
analysis [17, 21, 22].  
 
Statistical Methods 
  Comparison of women with and without HPV typing data was done using Pearson’s chi-
square test for independence evaluating various characteristic differences. Among those who had 
valid typing results, chi-square test for independence was used to evaluate differences between 
individual level variables and the primary outcome, which was having vaccine type HPV (16 
and/or 18 with or without another type) or having non-vaccine type HPV (anything other than 
HPV 16 or 18). Individual information was collected from the best data available including a 
combination of chart reviews and interviews. The Cochran-Armitage test for trend was used to 
evaluate if a statistically significant gradient existed by levels of the area-based measures. Trend 
analysis was appropriate for these measures because categories were listed in increasing 
proportions.  
The selected variables included area-based measurements of proportion of population 
black, proportion of population Hispanic, and proportion of population living below federal 
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poverty level. Individual level variables included age, race/ethnicity, insurance, diagnosis, and 
diagnosis year. Age was grouped into 5 different categories based in part on recent guidelines 
recommending initial Pap smear screening at age 21 years and included 18-20, 21-24, 25-29, 30-
34, and 35-39 years. The individual level race/ethnicity characteristic was separated into 5 
categories: non-Hispanic white, non-Hispanic black, Hispanic, other, and unknown. The 
category “other” included American Indian, Asian, multiple, and “other” races. These races were 
combined into one category because of small numbers of women. Insurance was comprised of 
private insurance, (including HMO/PPO/Managed Care/VA insurances), public insurance 
(including Medicare/Medicaid), and no insurance (including women who self-paid or had no 
insurance). Diagnosis was comprised of 5 categories of increasing severity including CIN2, 
CIN2/3 (i.e., grade not specified), CIN3, AIS, and AIS+CIN. Diagnosis year includes the first 
three years that the program has been active (2008, 2009, 2010) and represents the year that the 
first diagnostic report for a case was received.  
The prevalence of selected HPV types (16, 18, 31, 35, 45, 51, 52, and 58) by race and 
ethnicity was completed using adjusted, race-specific denominators that accounted for women 
with multiple HPV types. For example, a white woman infected with 2 HPV types would be 
counted twice for the white-specific denominator. These types were chosen either due to their 
respective prevalence within our data (e.g., sufficient sample size) or due to implications from 
the literature that racial and ethnic disparities may exist [6, 18]. 
Unadjusted and adjusted odds ratios and 95% confidence intervals were calculated for all 
variables. The generalized estimating equation (GEE) was used to calculate unadjusted odds 
ratios for all area-based measures to account for correlations within census tracts and logistic 
regression was used to calculate all individual level variables. The adjusted odds ratios represent 
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a full model including all variables and was calculated using GEE. SAS (v 9.2, SAS Institute, 
Cary, NC, 2002) was used to complete all statistical analyses.  
 
Results 
 From 2008-2010, a total of 1,804 New Haven County women aged 18-39 diagnosed with 
CIN2+ were reported to the HPV-IMPACT monitoring system at the Connecticut site. Of these 
1,804 women, 917 of them had HPV typing completed. A total of 887 did not have HPV typing 
results available because specimens had not been requested from pathology labs (n=234, 26.4%), 
requests were still pending from pathology labs (n=327, 36.9%), pathology labs deemed 
specimens insufficient (n=169, 19.0%) or specimen typing results were still pending at the CDC 
(n=157, 17.7%). CIN2+ cases with HPV DNA typing were not similar to cases without typing 
with respect to all demographic characteristics. Women with typing data were more likely to be 
18-20 years and less likely to be 35-39 years. They were more likely to be white or Hispanic and 
less likely to be black. They were more likely to have a CIN 3 diagnosis and less likely to have a 
CIN 2 diagnosis. Finally, they were more likely to be diagnosed with CIN2+ in 2008 and less 
likely to be diagnosed in 2010 compared to women without typing data. However, with the 
exception of year, the magnitudes of these differences were not large. 
 Table 2 presents all of the detected HPV types in eight mutually exclusive categories. Of 
the 917 women who had specimens typed, HPV DNA was not detected in specimens for 47 
women (5.1%). A total of 275 women (30%) had a single infection of HPV 16; 29 women 
(3.2%) had a single infection of HPV 18; and only one woman had a co-infection with types 16 
and 18. Women with one or more non-vaccine HPV types made up 53% of the sample (n=486). 
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Graph 1 presents the specific HPV type prevalence among our sample size. The top 5 types with 
the highest prevalence were 16 (37.7%), 31 (11.6%), 52 (10.8%), 51 (9.8%), and 35 (6.0%).  
 Table 3 presents the percentage of cases with each characteristic by vaccine-type HPV 
versus non-vaccine type HPV and includes unadjusted and adjusted odds ratios with 95% 
confidence intervals. For the area-based measure of proportion of the population living below the 
federal poverty level, a significant trend existed (p=0.05). As the proportion of poverty 
increased, the percentage of women with non-vaccine type HPV increased and the percentage of 
women with vaccine type HPV decreased. This same trend existed at a nearly statistically 
significant level for the variables proportion population black (p=0.11) or Hispanic (p=0.06). For 
these area-based variables, results show that women who live in areas with higher proportions of 
the population black or Hispanic (≥20%) have higher percentages of non-vaccine type than 
vaccine type HPV. In categories with the lowest proportions of population black, Hispanic, or 
living below poverty level (<5%), vaccine type and non-vaccine type HPV occur at about 50% 
each. For individual level characteristics, the percentage of those with HPV vaccine types 
differed by age, race/ethnicity, and diagnosis at statistically significant levels. A higher 
percentage of women with CIN2 had non-vaccine type HPV (64.5%) compared to vaccine type 
(35.5%), while vaccine type HPV accounted for all AIS cases and a larger proportion of CIN3 
diagnoses (59.5% vs. 40.5%). Women aged 21-29 years made up the majority of the sample for 
both vaccine type (64.3%) and non-vaccine type HPV (53.9%). Among women aged 18-20 
years, a larger proportion of non-vaccine type HPV (64.0%) was discovered compared to vaccine 
type HPV (36.1%). The same trend existed for women 21-24, but changed among women 25-29 
years with 51.4% vaccine type HPV. Women 30-34 and 35-39 years had significantly more non-
vaccine HPV. Among white women there was nearly a 50% split between those who had vaccine 
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type and those who did not. Black women had a higher percentage of non-vaccine type HPV 
(63.8%) than vaccine type (36.2%). Hispanic women also had higher percentages of non-vaccine 
type HPV (61.2%).  
Unadjusted odds ratios for all variables followed the same trends given by chi-square 
analyses, while the adjusted odds ratio for proportion population black revealed a significant 
reverse association between the variable and vaccine type HPV. Results showed the adjusted 
odds ratios predicting vaccine type HPV increased when the proportion of population black 
increased.  
Table 4 shows HPV type prevalence by race and ethnicity. Specific type distribution by 
race/ethnicity revealed that HPV type 16 accounted for 37.6%, 26.8%, and 26.5% of types found 
in white, black, and Hispanic women. HPV type 35 accounted for 3.5%, 10.7%, and 6.5% of all 
infections for each respective race or ethnicity. HPV type 58 accounted for 2.6%, 13.4%, and 
6.5% of all infections for each respective race or ethnicity. Together, non-vaccine types 35, 52, 
and 58 accounted for 35.8% of the HPV found among black women, 23.3% of HPV among 
Hispanic women and 14.8% of HPV among white women. 	  
Discussion  
 This analysis expands the current literature on the distribution of HPV types among 
women of different SES backgrounds as well as adds to the general knowledge about HPV types 
found in precancerous lesions CIN2+. Analyzing the distribution of HPV types by SES factors is 
important in determining the prevention potential of the current HPV vaccines and monitoring 
the impact as well as helping to pinpoint SES disparities that confer elevated risks for HPV types 
not covered by the current vaccine. This is an important public health issue because disparate 
HPV type distribution means that certain populations of women are less likely to be protected 
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against cervical cancer and precursors given the current HPV types included in the bivalent and 
quadrivalent vaccines.  
An intriguing result from this study is the difference in distribution of vaccine type HPV 
by individual and area-based measures of race/ethnicity. Results show that non-Hispanic black 
and Hispanic women are less likely to have vaccine type HPV (16/18) and more likely to have 
non-vaccine type HPV. This is also reflected in the area-based results of proportion population 
Hispanic and black. The individual level results are corroborated by the five site HPV-IMPACT 
analysis conducted by Centers for Disease Control [18], which examined HPV type and 
socioeconomic disparities at the individual level. The CDC investigation found similar disparate 
results showing that black and Hispanic women were less likely to have HPV 16/18. Our 
analysis is different because it included area-based characteristics, including poverty, as well as 
individual characteristics to analyze racial and ethnic disparities of HPV distribution. Both 
individual race/ethnicity and area-based levels of measurement show similar trends, although the 
area-based measure of poverty was the only significant variable. Proportion population Hispanic 
and black were not significant, but had clear increasing trends of non-vaccine type HPV as 
proportion population went from <5% black (53.8%) or Hispanic (51.6%) to >20% black 
(60.3%) or Hispanic (57.4%).   
A puzzling finding occurred for proportion population black when all variables were 
included in an adjusted GEE model. The results were opposite from the unadjusted results found 
in chi-square and odds ratio analysis. When the variable is included in a model on its own, odds 
ratios show a general decrease in risk of having vaccine type HPV as proportion population 
black increased. However, when the full model including all variables was examined, the area-
based race variable predicted an increasing risk for vaccine type HPV as proportion population 
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black increased. This was the only variable in the full model that gave significantly different 
results from what was seen in the unadjusted models. The reason for this result is unclear and 
warrants further investigation. The proportion population Hispanic may be influencing this 
result. It is possible that there is negative confounding that could be further explored in a 
stratified analysis. 
The results suggest that HPV types not covered by the vaccine are causing a significant 
proportion of precancerous lesions among racial and ethnic minorities adding to the various 
factors responsible for cervical cancer disparities in the United States. Furthermore, the CDC 
study also found more HPV35 and 58 in non-Hispanic blacks and HPV45 in Hispanics compared 
to non-Hispanic whites [18]. This finding was also true for the type distribution among the 
women in our sample. However, this is not surprising because the data used in this analysis was 
a subset of data used in the CDC analysis. Non-vaccine types 35, 52, and 58 (all found in the top 
6 most prevalent types of the study) together accounted for 35.8% of the HPV found among the 
black sample, 23.3% of HPV among the Hispanic sample yet only 14.8% of HPV among the 
white sample. Worldwide studies on HPV type distribution show that other HPV types, such as 
35 and 58 in Africa, are responsible for a higher proportion of high-grade lesions than in North 
America and Europe [6]. Another study showed that women in sub-Saharan Africa were less 
likely to be infected with HPV16 than women in Europe and were more likely to have other 
high-risk HPV type infections [23]. These circulating types appear to be significant contributors 
to high-grade lesion morbidity among minority women in the United States. 
The new 9-valent HPV vaccine developed by Merck is currently in phase III trials and 
protects against HPV types included in the current quadrivalent vaccine and additional types that 
this analysis implicates as producing a large proportion of precancerous lesions among minority 
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women. The new HPV types that the vaccine will cover are -31, -33, -45, -52, and -58. This 
analysis shows that the inclusion of types 52 and 58 would aid in reducing cervical lesions 
among minority women who receive the vaccine. However, according to this analysis and the 
CDC analysis, the exclusion of type 35 may produce disparate distributions yet again [18]. The 
results of this analysis show that type 35 is responsible for 3.5%, 10.7%, and 6.5% of HPV 
infection among white, black and Hispanic women respectively. Although Guan et al. suggest 
that type 35 has lower levels of carcinogenicity, they also show that this type is responsible for a 
large proportion of high-grade lesions in Africa [6]. However, the results from this study do 
suggest that type 35 could be an important type that is being overlooked.  
 Many of the results of this evaluation are consistent with the current literature showing 
that HPV 16 and 18 are responsible for the majority of higher grade lesions and AIS [6, 9, 23]. 
As expected, of the 4 women with reports of AIS, 3 tested positive for HPV 18 only and 1 tested 
positive for type 18 plus one or more other non-vaccine type HPV. More vaccine type HPV was 
found in diagnoses more advanced than CIN2, while the opposite was true for CIN2 diagnoses. 
 This analysis had several limitations. First, women who had typing data available were 
significantly different from women without typing data for all characteristics. However, 
specimens sent for typing were not selected based on personal characteristics of the cases thus 
any difference between groups should not be systematic. Second, only about half of the reported 
cases had typing data available due to the fact that samples are typed based on convenience of 
availability in this routine public health surveillance activity. Thus, the cases who have yet to be 
typed may contribute different results than the typed cases used in this analysis. Third, it is 
possible that some of the cases in our study received one of the available HPV vaccines that have 
been available since 2006, affecting the typing results. Fourth, we use the term “vaccine-type 
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HPV” to mean HPV 16 and/or 18 with or without any other HPV type. Since some cases had 
HPV16 and/or 18 accompanied by one or more non-vaccine type HPV (20.6% of cases with 
vaccine type HPV) it is impossible to definitively parse out which type was responsible for the 
cervical lesions. However, some research shows the synergistic effect of having multiple HPV 
infections especially when one of the types consists of 16 or 18 [24]. Finally, this analysis may 
not generalize beyond New Haven County, Connecticut. However, NHC has comparable 
proportion statistics to the rest of the United States for race and ethnicity categories of black, 
white, and Hispanic/Latino. NHC had 1.4% higher white population, a 1.3% lower Hispanic 
population and a 0.01% higher black population compared to the United States. NHC is more 
comparable to the United States in terms of race and ethnicity than Connecticut as a whole [25]. 
Furthermore, a strength of this analysis is the high case ascertainment and therefore large sample 
size achieved within the NHC catchment area due to the mandatory reporting of CIN2+ and the 
cooperation of pathology laboratories, which limits selection bias and strengthens the internal 
validity of the study.  
This study adds to the available baseline data on HPV type prevalence in order to aid in 
measuring the wide-scale impact of the HPV vaccine in the next decade. This analysis suggests 
that non-vaccine type HPV is an important contributing factor for high-grade lesions among 
women of different racial and ethnic backgrounds. This analysis also may help inform future 
multivalent HPV vaccine development endeavors that may be key to decreasing racial and ethnic 
cervical lesion and cancer disparities. 	  
	  
Future Implications 
This analysis will aid future interpretations of surveillance data regarding impact of 
vaccination given that certain HPV types seem to be more prevalent among different race/ethnic 
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groups. HPV types not included in the current vaccines are causing a significant amount of 
precancerous lesion morbidity among minority women and should be considered for future 
multi-valent HPV vaccines that will “level the playing field” in terms of risk among different 
races and ethnicities. Area-based as well as individual characteristics seem to be important in 
determining risk for acquiring vaccine type HPV and therefore should be considered for future 
analyses monitoring vaccine impact. Furthermore, the different results in unadjusted and 
adjusted models suggest a complex interplay between individual and area based measurements 
that warrant further investigation. Area-based measurements may contribute new and different 
data compared to individual measurements of race and ethnicity that can help parse out 
individual risk factors compared to broader social and environmental risk factors.  
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Table 1. HPV typed samples versus not typed samples among women aged 18-39 years with 
CIN2+ reports during 2008-2010 by selected characteristics.  
   NHC Women with CIN2+ Reports (Total=1804) 
Characteristic 
Typed  
 N = 917 (50.8) 
Not Typed  
N = 887 (49.2) p-value 
Age   0.016 
18-20 91 (9.9) 50 (5.6)  
     21-24 260 (28.4) 253 (28.5)  
     25-29 275 (30.0) 283 (31.9)  
30-34 179 (19.5) 177 (20.0)  
     35-39 112 (12.2) 124 (14.0)  
 Race/Ethnicity   <0.001 
     NH White 474 (51.7) 373 (42.1)  
     NH Black 96 (10.5) 110 (12.4)  
     Hispanic 153 (16.7) 133 (15.0)  
Other 41 (4.5) 39 (4.4)  
Unknown 153 (16.7) 232 (26.2)  
Insurance   <0.001 
     Private 588 (65.5) 486 (57.0)  
Public 289 (32.2) 322 (37.8)  
No Insurance 18 (2) 36 (4.2)  
     Other 3 (0.3) 8 (0.9)  
Diagnosis   0.02 
CIN 2 580 (63.3) 614 (69.2)  
CIN 2/3 130 (14.2) 89 (10.0)  
CIN 3 201 (21.3) 179 (20.2)  
AIS 4 (0.4) 5 (0.6)  
AIS+CIN 2 (0.2) 0 (0.0)  
Diagnosis Year   <0.001 
2008 509 (55.5) 161 (18.15)  
2009 297 (32.4) 288 (32.5)  















	   22 














































HPV Type  
16 only 275 (30.0) 
16+18 only 1 (0.1) 
16+ any non vacc. type 66 (7.2) 
18 only 29 (3.2) 
18+ any non vacc. type 9 (1.0) 
16+18+ any non vacc. type 4 (0.4) 
Non vacc. type only 486 (53.0) 
No type 47 (5.1) 
Total 917 
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Table 3. HPV Type by Area-Based and Individual Level Characteristics 












Proportion pop. black   0.11*   
<5.0 178 (46.2) 207 (53.8)  1  1 
5.0-9.9 45 (47.9) 49 (52.1)  1.02 (0.91, 1.14) 1.09 (0.98. 1.22) 
10.0-19.9 69 (43.4) 90 (56.6)  0.97 (0.88, 1.07) 1.11 (1.0, 1.24) 
≥ 20 92(39.7) 140 (60.3)  0.94 (0.87, 1.01) 1.12 (1.01, 1.25) 
Proportion pop. Hispanic   0.06*   
<5.0 104 (48.4) 111 (51.6)  1 1 
5.0-9.9 117 (48.2) 126 (51.9)  1.0 (0.91, 1.09) 0.98 (0.89, 1.08) 
10.0-19.9 68 (36.0) 121 (64.0)  0.88 (0.80, 0.97) 0.86 (0.77, 0.96) 
≥ 20 95 (42.6) 128 (57.4)  0.94 (0.86, 1.03) 0.97 (0.85, 1.10) 
Proportion pop. living 
below federal poverty level   0.05* 
  
<5.0 139 (49.5) 142 (50.5)  1 1 
5.0-9.9 90 (42.5) 122 (57.6)  0.93 (0.85,1.02)  0.97 (0.89, 1.06) 
10.0-19.9 84 (42.0) 116 (58.0)  0.93 (0.85, 1.01) 0.93 (0.83, 1.03) 
≥ 20 71 (40.1) 106 (59.9)  0.91 (0.83, 1.0) 0.89 (0.78, 1.02) 
Age   0.02   
   18-20 31 (36.1) 55 (64.0)  0.81 (0.45, 1.46) 1.0 (0.88, 1.14) 
   21-24 115 (45.6) 137 (54.4)  1.21 (0.76, 1.92) 1.09 (0.97, 1.22) 
   25-29 132 (51.4) 125 (48.6)  1.52 (0.96, 2.4) 1.13 (1.0, 1.28) 
   30-34 63 (37.1) 107 (62.9)  0.85 (0.52, 1.40) 0.98 (0.86, 1.11) 
   35-39 43 (41.0) 62 (59.1)  1 1 
Race/Ethnicity   0.01   
     White 224 (50.1) 223 (48.9)  1 1 
     Black 34 (36.2) 60 (63.8)  0.56 (0.36, 0.89) 0.91 (0.80, 1.04) 
     Hispanic 57 (38.8) 90 (61.2)  0.63 (0.43, 0.92) 0.91 (0.82, 1.0) 
Other 13 (33.3) 26 (66.7)  0.50 (0.25, 0.99) 0.90 (0.77, 1.06) 
Unknown 56 (39.2) 87 (60.8)  0.64 (0.44, 0.94) 0.92 (0.82, 1.03) 
Insurance   0.45   
     Private 248 (44.6) 308 (55.4)  1 1 
Public 122 (44.5) 152 (55.5)  1.0 (0.75, 1.33) 1.0 (0.93, 1.08 
No Insurance 7 (38.9) 11 (61.1)  0.79 (0.30, 2.07) 1.01 (0.77, 1.33) 
     Other 0 (0.0) 3 (100.0)  
<.01 
 (<.01, >999.99) 
0.57 (0.51, 0.66) 
Diagnosis   <0.001   
CIN 2 193 (35.5) 350 (64.5)  1 1 
CIN 2/3 69 (54.8) 57 (45.2)  2.20 (1.48, 3.25) 1.23 (1.12, 1.35) 
CIN 3 116 (59.5) 79 (40.5)  2.66 (1.90, 3.73) 1.30 (1.17, 1.36) 
AIS 4 (100.0) 0 (0.0)  
>999.99  
(<.01, >999.99) 
1.92 (1.70, 2.17) 
AIS+CIN 2 (100.0) 0 (0.0)  
>999.99  
(<.01, >999.99) 
1.91 (1.54, 2.37) 
Diagnosis Year   0.55   
2008 219 (45.1) 267 (54.9)  1 1 
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2009 116 (41.6) 163 (58.4)  0.87 (0.64, 1.17) 0.97 (0.91, 1.04) 
2010 49 (46.7) 56 (53.3)  1.07 (0.70, 1.63) 1.0 (0.90, 1.11) 
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Table 4. Percentage of HPV Type Found Among Women of Selected Race/Ethnicities 
 16 18 31 35 45  51 52 58 
Race/Ethnicity         
   White 37.6 4.1 10.5 3.5 1.1 9.2 8.7 2.6 
   Black 26.8 4.5 0.9 10.7 1.8 7.1 11.6 13.4 
   Hispanic 26.5 4.9 10.8 6.5 2.2 7.0 10.3 6.5 
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